

Stem cell and regenerative medicine: Commercial and pharmaceutical implications

Eduardo Cruz

Axis BiotecBrasil Group, Brazil

The overall population of the world is getting older. People live longer and look forward to living better. Degenerative disease becomes a grand concern and tremendous challenge to governments and healthcare institutions. In the United States myocardial degenerative disease and stroke are the leading cause of death and represent outstanding medicare costs. New drugs have made heart attack death rate decrease considerably in the last 30 years, but still millions of surviving patients will proceed to heart failure status (congestive heart failure, for example). Tissue engineering and cell therapy will play a major role in this challenging but promising new era of citizens of a planet where being over 85 will mean having a joyful life.

The great therapeutic potential of stem cells in treating degenerative diseases can be rationalized, as cell therapy and tissue engineering may be considered the most relevant window of opportunity in health-related business for the dawn of the 21st century.

Most of the companies involved in Cell Therapy and Tissue Engineering are small, highly sophisticated in terms of qualified staff, and privately owned and funded. It is to know that an innovative product will demand several millions of dollars and take from 8 to 10 years from laboratory to the bedside. Somehow in the early years of 21st century larger pharmaceutical groups turned their attention to this promising land.

Will autologous cell transplantation become a standard medical procedure? Will off-the-shelf cell treatments soon be packaged, prescribed, and routinely used in the hospital environment? How to translate scientific research into innovative products and services in cell therapy?

Biography

Eduardo Cruz is Biochemist Pharmacist, MD, MBA in Marketing and Finances. He has been working in R,D&B since 1980, launched to market many drugs and managed the development of new biomaterials, products for regenerative medicine among others. Eduardo has more than 15 papers published in reputed journals and is also author of book chapters and holder of patents and trademarks. He is the founder and CEO of Axis BiotecBrasil Group (Silvestre Labs, Cryopraxis, CellPraxis Bioengineering and PharmaPraxis). Axis BiotecBrasil is a holding company that presents a history of success in translating research into innovative products and services.

marcasepatentes@cryopraxis.com.br